Winkelwagen
U heeft geen artikelen in uw winkelwagen
The American Academy of Dermatology gratefully acknowledges the support from Sanofi and Regeneron.
Diseases>Eczema>Sanofi-Regeneron Logo>2022" />
Hives are itchy welts on the skin. They can be caused by:
Regardless of what they look like, hives tend to appear and clear within a few hours. Some people have one flare-up and never get hives again. It’s also possible to have many flare-ups.
If you continue to get hives daily or almost every day for six weeks or longer, you have chronic hives. The medical term for this is “chronic urticaria."
When you have chronic hives, the most effective treatment often depends on the type of the hives you have and your medical history.
Often the management for chronic inducible urticaria and chronic spontaneous urticaria will overlap.
An algorithm for the symptomatic treatment of chronic urticaria is included in the international guidelines (see figure 4). The algorithm should be used with caution in children with chronic urticaria and in pregnant/lactating women as drugs contraindicated in pregnancy should not be used. Treatment should be continued until remission occurs.
Figure 4 - Pharmacological treatment algorithm for chronic urticaria
Many symptoms of urticaria are mediated by the actions of histamine on H1-receptors located on antihistamines is supported by clinical trial data. In some forms of physical urticaria, such as cold urticaria, ‘as required’ treatment may be appropriate.
Second-generation antihistamines are recommended in preference to first-generation antihistamines, as the latter have anticholinergic effects and sedative actions, and they interact with alcohol and many drugs that affect the central nervous system. Second-generation non-sedating antihistamines are the first-line symptomatic treatment for urticaria because of their good safety profiles. Those studied in the treatment of chronic urticaria include:
Terfenadine and astemizole are no longer available in New Zealand or Australia and should not be used as they are cardiotoxic in combination with ketoconazole or erythromycin.
Recently, new guidelines have been published by the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the European Academy of Allergy and Clinical Immunology (EAACI)/Global Allergy and Asthma European Network (GA 2 LEN)/European Dermatology Forum (EDF)/World Allergy Organization (WAO) that update what is currently understood about urticaria 3– 5 . There are several other published regional guidelines with similar recommendations, including Canadian 11 . With the exception of the American guidelines, the other organizations put forth a similar algorithm. That is, the following stepwise approach: first-line treatment includes second-generation H 1 antihistamines, second-line therapy involves up-dosing the second-generation H 1 antihistamine, and third-line treatment includes a new medication, omalizumab, which we recommend to be used before a more toxic medication, cyclosporine A.
The EAACI/GA 2 LEN/EDF/WAO guidelines do not include H 2 antihistamines in their algorithm due to a recent Cochrane review that shows lack of evidence of efficacy of these medications 13 . Thus, H 2 antihistamines are advised only on an individual case basis but not as first-, second- or third-line treatment. The AAAAI guidelines, however, consider the options of up-dosing second-generation H 1 antihistamines, adding other second-generation H 1 antihistamines, and adding H 2 antagonists, leukotriene receptor antagonists or first-generation H 1 antihistamines at bedtime to all be equally weighted second-line options 3 . In doing this, however, the adverse reaction profile would increase.
Both guidelines recommend that corticosteroids should be considered only for the short-term intervention and avoided as long-term treatments due to the significant number of side effects and alternative options for treatment. Both guidelines also acknowledge a role for cyclosporine A as an add-on treatment for patients who have refractory chronic urticaria that is not responsive to the above mentioned treatments 3, 5 .
Patients with chronic spontaneous urticaria may experience sleep deprivation, anxiety, depression, lack of energy, and social isolation. These can result in a significant deterioration in the patient's quality of life (see figure 2). Chronic spontaneous urticaria is unpredictable and can disrupt the patient’s normal daily activities.
Figure 2 - Impact of chronic spontaneous urticaria on quality of life, sleep and daily activities
Note: Higher score indicates greater impairment of quality of life.
Credit: Adapted from Maurer M, et al. Allergy 2017, 72: 2005–16.